ViaDerma, Inc. Looks to File Additional Patents & License New Products for its (MMJ) Medical Marijuana Patent Pending Delivery Technology with Licensed Dispensaries
Marketwired MarketwiredFebruary 15, 2017Comment
LOS ANGELES, CA--(Marketwired - February 15, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today the "New Intellectual Property" & "New Products Initiative" will focus on creating new products and filing new patents to treat pain and certain diseases associated with inflammation. The company expects treatment success of ViaDerma's "Proprietary Delivery System" for several diseases by finding the "Optimal Transdermal Delivery" of CBD's & THC to the localized treatment area and into the blood stream. With regards to the patent pending use of its innovative transdermal system for the delivery of (CBD's) Calanoids and (THC) tetrahydrocannabinol for the treatment of several diseases. The transdermal system can deliver through topical skin absorption to localized areas and directly into the blood stream. The provisional patent application using the combination of CBD's with the delivery system was originally filed in 2014, and a new provisional patent will be filed this week. The patent pending transdermal system can deliver medications and nutrients into the body through the skin.
The use of CBD's is known for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. "For example, a person with a migraine headache can place the CBD and THC combined with the delivery compound and apply to the neck with immediate absorption into the bloodstream through the carotid artery," said Dr. Christopher Otiko, CEO. "We are also in the clinical testing stages of an anti-aging topical solution, topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido."
ViaDerma sees the use of CBD's along with our Proprietary transdermal delivery system for the treatment and continuing studies looks very promising and demonstrates efficacy in terms of treating several unrelated diseases. "We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community," said Dr. Christopher Otiko, ViaDerma's founder and CEO.
